$TEM Stock Surges on Positive Cancer Vaccine Trial Results

Tempus AI's stock has seen a sharp rally following positive Phase 3 results from a Moderna-Merck cancer vaccine trial, which validates the company's precision medicine platform and related investments. This development has led to increased volume and a decisive move out of a multi-month consolidation pattern, with the stock approaching prior highs amid broader sector strength in healthcare technology.

While some have raised concerns over elevated stock-based compensation and acquisition-driven growth, excitement prevails over potential reimbursement gains and platform expansion in the coming years. Analysts have set price targets for $TEM, with a median target of $64.0, while institutional investors such as JPMORGAN CHASE & CO, GOLDMAN SACHS GROUP INC, and CITADEL ADVISORS LLC have added significant shares to their portfolios.

Tempus AI insiders have traded $TEM stock on the open market 71 times in the past six months, with CEO Eric P Lefkofsky selling 1,069,926 shares for an estimated $51,608,531. The company's revenue has increased by 21.56% to $382.5M in Q2 2026.